


I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 544974675 US in an envelope addressed to: MS RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: November 17, 2005 Signature: 

(Debra J. Glaister)

Patent

Docket No. 377882001300

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Re Patent Application of:  
Gary VAN NEST et al.

Serial No.: 09/802,445

Filing Date: March 9, 2001

For: METHODS OF REDUCING  
PAPILLOMAVIRUS INFECTION  
USING IMMUNOMODULATORY  
POLYNUCLEOTIDE SEQUENCES

Examiner: Z. Lucas

Group Art Unit: 1648

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

This Supplemental Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☒ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.

- ☐ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
- ☐ A fee is required. A check in the amount of \_\_\_ is enclosed.
- ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of \_\_\_ is enclosed.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other


Application Serial No. 09/802,445

Patent  
Docket No. 377882001300

fees due in connection with the filing of this document to **Deposit Account No. 03-1952**  
referencing 377882001300.

Dated: November 17, 2005

Respectfully submitted,

By 

Debra J. Glaister

Registration No.: 33,888  
MORRISON & FOERSTER LLP  
755 Page Mill Road  
Palo Alto, California 94304-1018  
(650) 813-5725

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		Application Number	09/802,445
		Filing Date	March 9, 2001
		First Named Inventor	Gary VAN NEST
		Art Unit	1648
		Examiner Name	Z. Lucas
		Attorney Docket Number	377882001300
Sheet	1	of	2


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US-2002/0028784-A1	03-07-2002	Nest	
	2.	US-2001/0046967-A1	11-29-2001	Van Nest	
	3.	US-2002/0098199-A1	07-25-2002	Van Nest et al.	
	4.	US-2003/0050263-A1	03-13-2003	Krieg et al.	
	5.	US-2003/0216340-A1	11-20-2003	Van Nest et al.	
	6.	US-2004/0009942-A1	01-15-2004	Van Nest	
	7.	US-2004/0030118-A1	02-12-2004	Wagner et al.	
	8.	US-2005/0059626-A1	03-17-2005	Van Nest et al.	
	9.	US-6,339,068-B1	01-15-2002	Krieg et al.	
	10.	US-6,406,705-B1	06-18-2002	Davis et al.	
	11.	US-6,498,148-B1	12-24-2002	Raz	
	12.	US-6,534,062-B2	03-18-2003	Raz et al.	
	13.	US-6,552,006-B2	04-22-2003	Raz et al.	
	14.	US-6,613,751-B2	09-02-2003	Raz et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	15.	WO-01/68117-A2,A3	09-20-2001	Dynavax Technologies Corporation	
	16.	WO-01/76642-A1	10-18-2001	The Regents of the University of California	

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	17.	Current Drugs Ltd. (February 24, 2003). "Lilly and 3M Suspend Resiquimod Trials," located at < <a href="http://www.iddb.com/iddb3/iddb3_2/reports.print_display?i_query_id=0&amp;template=Refe...">http://www.iddb.com/iddb3/iddb3_2/reports.print_display?i_query_id=0&amp;template=Refe...</a> >, last visited on October 13, 2005, 1 page.		
	18.	Current Drugs Ltd. (February 24, 2003). "Preliminary Data from Recently Completed Clinical Trials of Resiquimod Suggest Dosing Used in Studies will not Achieve Adequate Efficacy," located at < <a href="http://www.iddb.com/iddb3/iddb3_2/reports.print_display?i_query_id=0&amp;template=Refe...">http://www.iddb.com/iddb3/iddb3_2/reports.print_display?i_query_id=0&amp;template=Refe...</a> >, last visited on October 13, 2005, 1 page.		
	19.	Guerrero-Plata, A. et al. (August 2005). "Activity and Regulation of Alpha Interferon in Respiratory Syncytial Virus and Human Metapneumovirus Experimental Infections," <i>Journal of Virology</i> 79(16):10190-10199.		
	20.	Huang, Z. et al. (August 2003). "Newcastle Disease Virus V Protein is Associated with Viral Pathogenesis and Functions as an Alpha Interferon Antagonist," <i>Journal of Virology</i> 77(16):8676-8685.		

Examiner Signature	Date Considered
--------------------	-----------------



ALTERNATIVE TO PTO/SB/08a/b (07-05)

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/802,445
				Filing Date	March 9, 2001
				First Named Inventor	Gary VAN NEST
				Art Unit	1648
				Examiner Name	Z. Lucas
Sheet	2	of	2	Attorney Docket Number	377882001300

21.	International Search Report mailed June 17, 2002 for PCT Application No. PCT/US01/07839 filed March 12, 2001, 6 pages.	
22.	International Search Report mailed June 18, 2002 for PCT Application No. PCT/US01/07841 filed March 12, 2001, 6 pages.	
23.	International Search Report mailed June 17, 2002 for PCT Application No. PCT/US01/07931 filed March 12, 2001, 7 pages.	
24.	International Search Report mailed June 17, 2002 for PCT Application No. PCT/US01/07842 filed March 12, 2001, 6 pages.	
25.	International Search Report mailed June 17, 2002 for PCT Application No. PCT/US01/07840 filed March 12, 2001, 6 pages.	
26.	Jones, M. et al. (May 2005). "Dengue Virus Inhibits Alpha Interferon Signaling by Reducing STAT2 Expression," <i>Journal of Virology</i> 79(9):5414-5420.	
27.	Lin, R.-J. et al. (September 2004). "Blocking of the Alpha Interferon-Induced Jak-Stat Signaling Pathway by Japanese Encephalitis Virus Infection," <i>Journal of Virology</i> 78(17):9285-9294.	
28.	Pantelic, L. et al. (February 2005). "Differential Induction of Antiviral Effects Against West Nile Virus in Primary Mouse Macrophages Derived for Flavivirus-Susceptible and Congenic Resistant Mice by Alpha/Beta Interferon and Poly(I-C)," <i>Journal of Virology</i> 79(3):1753-1764.	
29.	Porter, K.R. et al. (1998). "Protective Efficacy of a Dengue 2 DNA Vaccine in Mice and the Effect of CpG Immuno-stimulatory Motifs on Antibody Responses," <i>Arch. Virol.</i> 143:997-1003.	
30.	Rauthan, M. et al. (2004). "Oral Immunization of Mice with Japanese Encephalitis Virus Envelope Protein Synthesized in <i>Escherichia coli</i> Induces Anti-viral Antibodies," <i>Microbes and Infection</i> 6:1305-1311.	
31.	Seo, S.H. et al. (September 2002). "Lethal H5N1 Influenza Viruses Escape Host Anti-viral Cytokine Responses," <i>Nature Medicine</i> 8(9):950-954.	
32.	Silverman, E. et al. (2003). "Immunostimulatory DNA for Asthma," <i>Am. J. Respr. Cell Mol. Biol.</i> 28:645-647.	
33.	Smith, V.P. et al. (February 2002). "Inhibition of Interferons by Ectromelia Virus," <i>Journal of Virology</i> 76(3):1124-1134.	
34.	The University of Texas Medical Branch at Galveston. (Date Unknown). "New Drug Reduces Frequency of Genital Herpes Flare-ups," located at < <a href="http://www.utmb.edu/newsroom/01pr_archive/jul_2001/resiquimod.htm">http://www.utmb.edu/newsroom/01pr_archive/jul_2001/resiquimod.htm</a> >, last visited on November 17, 2005, 2 pages.	
35.	United States Patent Application No. 09/802,518 filed on March 9, 2001 for Van Nest, 58 pages.	
36.	Unknown. (Date Unknown). "Resiquimod (Topical), 3M," located at < <a href="http://www.iddb.com/iddb3/iddb3_2/reports.print_display?i_query_id=5874091&amp;template...">http://www.iddb.com/iddb3/iddb3_2/reports.print_display?i_query_id=5874091&amp;template...</a> >, last visited on October 7, 2005, 1 page.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

pa- 1026218